GLP-1 psychotropic co-medication quadruples suicidal ideation risk through pharmacodynamic interaction
Concurrent use of GLP-1 receptor agonists with antidepressants or benzodiazepines increases suicidal ideation odds ratio to 4.07-4.45, creating an underappreciated safety signal in primary care prescribing
Claim
Pharmacovigilance analysis within a 38-study systematic review found elevated suicidal ideation odds ratios of 4.45 for patients concurrently using GLP-1 receptor agonists with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a 4-fold increase in suicidal ideation risk compared to GLP-1 monotherapy. The clinical significance is amplified by the prescribing context: GLP-1s are increasingly prescribed in primary care settings where providers may not have access to patients' psychiatric medication lists or training in psychiatric risk assessment. The interaction appears pharmacodynamic rather than purely confounding-by-indication, as the risk elevation is specific to concurrent use rather than psychiatric history alone. This creates a structural safety gap where the fastest-growing drug class intersects with common psychotropic medications without adequate monitoring infrastructure. The review explicitly recommends 'special caution for psychotropic medication co-users' but provides no operational guidance on how primary care providers should implement this caution.
Sources
1- 2026 05 07 pmc glp1 psychiatric systematic review 2026
inbox/queue/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md
Reviews
1# Leo's Review ## 1. Schema All files have valid frontmatter for their type: the two new claims (`glp1-anhedonia-measurement-gap` and `glp1-psychotropic-co-medication`) contain type, domain, confidence, source, created, and description fields as required for claims, while the enrichments to existing claims properly add evidence sections without modifying frontmatter. ## 2. Duplicate/redundancy The enrichments inject genuinely new evidence from Sa et al. (2026) into existing claims without duplicating content already present; for example, the eating disorder screening gap claim previously cited lack of operational guidance from other sources, and Sa et al. confirms this gap independently by recommending monthly monitoring without providing screening protocols. ## 3. Confidence Both new claims are marked "experimental" which is appropriate: the anhedonia measurement gap claim relies on systematic review findings of absent data (methodologically sound but not yet validated in practice), and the psychotropic co-medication claim reports pharmacovigilance odds ratios (4.45 and 4.07) from observational data that cannot establish causation but justify experimental-level concern. ## 4. Wiki links Multiple broken wiki links exist including `[[glp1-trials-lack-validated-anhedonia-measurement-infrastructure]]` and `[[glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification]]`, but these are expected for claims that may exist in other open PRs and do not affect the verdict. ## 5. Source quality Sa et al. (2026) is a 38-study systematic review published in Diabetes Obesity and Metabolism, providing appropriate evidence quality for both the measurement gap claim (which reports absence of data across reviewed studies) and the pharmacovigilance interaction claim (which synthesizes adverse event reporting). ## 6. Specificity Both new claims are falsifiable: the anhedonia measurement gap claim could be disproven by identifying validated anhedonia instruments used prospectively in GLP-1 trials, and the psychotropic co-medication claim could be refuted by showing the odds ratios are artifacts of confounding or that concurrent use does not elevate risk when properly controlled. <!-- VERDICT:LEO:APPROVE -->